PALUMBO, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 12713
EU - Europa 8269
AS - Asia 6186
SA - Sud America 410
OC - Oceania 396
AF - Africa 217
Continente sconosciuto - Info sul continente non disponibili 29
Totale 28220
Nazione #
US - Stati Uniti d'America 12082
CN - Cina 3107
DE - Germania 2663
IT - Italia 1489
GB - Regno Unito 1236
JP - Giappone 920
IN - India 550
CA - Canada 546
KR - Corea 434
FR - Francia 384
ES - Italia 368
AU - Australia 331
PL - Polonia 301
NL - Olanda 298
RU - Federazione Russa 278
VN - Vietnam 240
BR - Brasile 184
CZ - Repubblica Ceca 171
CH - Svizzera 152
TW - Taiwan 134
TR - Turchia 128
ZA - Sudafrica 123
HK - Hong Kong 106
AT - Austria 101
ID - Indonesia 93
SE - Svezia 82
BE - Belgio 80
CO - Colombia 76
RO - Romania 76
UA - Ucraina 76
GR - Grecia 71
DK - Danimarca 69
CL - Cile 67
MX - Messico 67
NZ - Nuova Zelanda 65
IL - Israele 64
IE - Irlanda 63
PT - Portogallo 60
SG - Singapore 59
TH - Thailandia 52
NO - Norvegia 49
HU - Ungheria 42
PK - Pakistan 41
AR - Argentina 40
IQ - Iraq 34
LT - Lituania 33
MY - Malesia 32
PH - Filippine 32
SA - Arabia Saudita 31
DZ - Algeria 28
IR - Iran 26
EG - Egitto 25
FI - Finlandia 23
KW - Kuwait 22
SI - Slovenia 22
PE - Perù 20
EU - Europa 19
BG - Bulgaria 16
HR - Croazia 13
SK - Slovacchia (Repubblica Slovacca) 13
BD - Bangladesh 12
NG - Nigeria 12
EC - Ecuador 11
MA - Marocco 11
JO - Giordania 10
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
MK - Macedonia 8
EE - Estonia 7
IS - Islanda 7
NP - Nepal 7
UY - Uruguay 7
LB - Libano 6
LK - Sri Lanka 6
QA - Qatar 6
LV - Lettonia 5
RS - Serbia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AP - ???statistics.table.value.countryCode.AP??? 4
CY - Cipro 4
PS - Palestinian Territory 4
TN - Tunisia 4
VE - Venezuela 4
CU - Cuba 3
KZ - Kazakistan 3
MO - Macao, regione amministrativa speciale della Cina 3
SY - Repubblica araba siriana 3
A1 - ???statistics.table.value.countryCode.A1??? 2
AL - Albania 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
GH - Ghana 2
PA - Panama 2
SC - Seychelles 2
SV - El Salvador 2
TG - Togo 2
TJ - Tagikistan 2
ZM - Zambia 2
Totale 28205
Città #
Fairfield 1224
Houston 1041
Hangzhou 971
Woodbridge 786
Buffalo 646
Cambridge 586
Seattle 559
Ann Arbor 552
Ashburn 550
Santa Cruz 533
Wilmington 469
Beijing 433
Tokyo 306
Duncan 274
Nürnberg 230
Torino 229
Shanghai 216
Wuhan 186
Dong Ket 184
University Park 180
Warsaw 167
Pisa 159
Nanjing 138
Leawood 114
San Diego 112
Ottawa 109
London 107
Taipei 104
Guangzhou 102
New York 97
Bengaluru 96
Toronto 95
Phoenix 94
Muizenberg 90
Seoul 89
Mountain View 84
Clearwater 82
Turin 78
Rochester 77
Chicago 76
Norwalk 74
Las Vegas 73
Raritan 68
Los Angeles 66
Jakarta 63
Chengdu 61
Nizhniy Novgorod 60
Vienna 60
Central District 58
Milan 58
Zhengzhou 55
Newbury Park 52
Rome 51
Boston 44
Iowa City 43
Xian 43
Changsha 40
Barcelona 39
Lake Forest 39
Madrid 39
San Francisco 38
Fuzhou 37
Singapore 37
Berlin 36
Sydney 36
Jinan 34
Hyderabad 33
Osaka 33
São Paulo 33
Dallas 31
Princeton 31
Durham 30
Montréal 30
Riva 30
Tianjin 30
Melbourne 29
Provo 29
Easton 28
Lanzhou 28
Moscow 28
Paris 28
Florence 27
Hebei 27
New Delhi 27
Scranton 27
Auckland 26
Gurgaon 26
Polska 26
Bogotá 25
Deventer 25
Saint Louis 25
Santiago 25
Cleveland 24
Dearborn 24
Istanbul 24
Rostock 24
Saitama 24
Bari 23
Boekelo 23
Brisbane 23
Totale 14455
Nome #
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study, file e27ce428-8ced-2581-e053-d805fe0acbaa 4966
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial., file e27ce427-8985-2581-e053-d805fe0acbaa 1686
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial, file e27ce428-2810-2581-e053-d805fe0acbaa 1261
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches., file e27ce426-ccce-2581-e053-d805fe0acbaa 1232
Continuous lenalidomide treatment for newly diagnosed multiple myeloma, file e27ce426-e897-2581-e053-d805fe0acbaa 844
Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma, file e27ce427-7977-2581-e053-d805fe0acbaa 680
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, file e27ce426-c622-2581-e053-d805fe0acbaa 608
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial., file e27ce426-e894-2581-e053-d805fe0acbaa 606
Efficacy and safety of once weekly bortezomib in multiple myeloma patients., file e27ce426-c502-2581-e053-d805fe0acbaa 536
Optimizing treatment for elderly patients with newly diagnosed multiple myeloma: A personalized approach, file e27ce42a-b7c1-2581-e053-d805fe0acbaa 524
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma, file e27ce42a-e94a-2581-e053-d805fe0acbaa 509
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma, file e27ce428-83bb-2581-e053-d805fe0acbaa 437
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)., file e27ce426-e896-2581-e053-d805fe0acbaa 434
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting), file e27ce428-a310-2581-e053-d805fe0acbaa 434
MET/HGF pathway in multiple myeloma: From diagnosis to targeted therapy?, file e27ce427-92ed-2581-e053-d805fe0acbaa 411
Management of older adults with multiple myeloma., file e27ce435-414b-2581-e053-d805fe0acbaa 351
Bendamustine for the treatment of multiple myeloma in first-line and relapsedrefractory settings: A review of clinical trial data, file e27ce427-8e9b-2581-e053-d805fe0acbaa 348
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma, file e27ce427-77e8-2581-e053-d805fe0acbaa 314
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens, file e27ce426-bdf2-2581-e053-d805fe0acbaa 298
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study., file e27ce427-a38f-2581-e053-d805fe0acbaa 296
Management of older patients with multiple myeloma, file e27ce426-d3d7-2581-e053-d805fe0acbaa 294
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone., file e27ce426-c501-2581-e053-d805fe0acbaa 284
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis, file e27ce426-c61f-2581-e053-d805fe0acbaa 283
How i treat fragile myeloma patients, file e27ce428-4de1-2581-e053-d805fe0acbaa 275
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients., file e27ce426-d3d5-2581-e053-d805fe0acbaa 274
Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network., file e27ce430-d0d8-2581-e053-d805fe0acbaa 274
The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents, file e27ce427-812e-2581-e053-d805fe0acbaa 264
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data., file e27ce435-4a9c-2581-e053-d805fe0acbaa 260
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma., file e27ce426-cd38-2581-e053-d805fe0acbaa 259
How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions, file e27ce426-d3d9-2581-e053-d805fe0acbaa 254
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma, file e27ce428-b171-2581-e053-d805fe0acbaa 251
Maintenance Therapy for Multiple Myeloma., file e27ce427-0b64-2581-e053-d805fe0acbaa 245
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone., file e27ce427-92e6-2581-e053-d805fe0acbaa 241
Role of consolidation/maintenance therapy in multiple myeloma., file e27ce427-0f1c-2581-e053-d805fe0acbaa 238
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies, file e27ce42d-6147-2581-e053-d805fe0acbaa 236
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma, file e27ce435-5f64-2581-e053-d805fe0acbaa 236
New pharmacotherapy options for multiple myeloma, file e27ce42f-6c42-2581-e053-d805fe0acbaa 234
Second primary malignancies in multiple myeloma: an overview and IMWG consensus, file e27ce42d-826c-2581-e053-d805fe0acbaa 227
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo, file e27ce426-bcf9-2581-e053-d805fe0acbaa 224
Sustained disease control in transplant-ineligible patients: the role of continuous therapy., file e27ce427-03b8-2581-e053-d805fe0acbaa 216
High-risk myeloma: when to transplant-or not., file e27ce427-8e9d-2581-e053-d805fe0acbaa 215
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles., file e27ce427-92e7-2581-e053-d805fe0acbaa 213
Immunotherapy: the next step in the treatment of myeloma, file e27ce428-8cc9-2581-e053-d805fe0acbaa 211
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies, file e27ce42d-6146-2581-e053-d805fe0acbaa 206
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, file e27ce427-7a2f-2581-e053-d805fe0acbaa 205
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients, file e27ce42a-ee98-2581-e053-d805fe0acbaa 205
Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement, file e27ce432-5189-2581-e053-d805fe0acbaa 204
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma, file e27ce427-8125-2581-e053-d805fe0acbaa 194
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)., file e27ce426-f790-2581-e053-d805fe0acbaa 193
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias, file e27ce426-c621-2581-e053-d805fe0acbaa 180
Initial treatment of nontransplant patients with multiple myeloma., file e27ce427-0f1d-2581-e053-d805fe0acbaa 180
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide, file e27ce426-aea7-2581-e053-d805fe0acbaa 179
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results, file e27ce427-86ab-2581-e053-d805fe0acbaa 179
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma, file e27ce432-dc72-2581-e053-d805fe0acbaa 174
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma, file e27ce426-ff25-2581-e053-d805fe0acbaa 171
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development., file e27ce426-c505-2581-e053-d805fe0acbaa 167
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma, file e27ce427-4b8d-2581-e053-d805fe0acbaa 158
Early response predicts myeloma outcome., file e27ce426-c500-2581-e053-d805fe0acbaa 155
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma, file e27ce427-79db-2581-e053-d805fe0acbaa 154
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma., file e27ce426-f782-2581-e053-d805fe0acbaa 149
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma, file e27ce427-78a4-2581-e053-d805fe0acbaa 149
Balancing act for elderly myeloma., file e27ce426-c503-2581-e053-d805fe0acbaa 148
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2., file e27ce426-e895-2581-e053-d805fe0acbaa 142
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study, file e27ce427-7c64-2581-e053-d805fe0acbaa 141
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance., file e27ce427-0f1e-2581-e053-d805fe0acbaa 140
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, nordic and turkish myeloma study groups, file e27ce427-8421-2581-e053-d805fe0acbaa 139
Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy., file e27ce426-ebf5-2581-e053-d805fe0acbaa 136
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: Use of “progression-free survival 2” as a clinical trial end-point, file e27ce427-7836-2581-e053-d805fe0acbaa 133
Treatment of newly diagnosed myeloma, file e27ce426-c620-2581-e053-d805fe0acbaa 132
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis, file e27ce427-8270-2581-e053-d805fe0acbaa 131
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial., file e27ce427-8f3b-2581-e053-d805fe0acbaa 131
Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives., file e27ce427-86a7-2581-e053-d805fe0acbaa 123
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome., file e27ce427-8aca-2581-e053-d805fe0acbaa 121
Lenalidomide in the treatment of lymphoproliferative disorders and multiple myeloma., file e27ce427-86a9-2581-e053-d805fe0acbaa 120
Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis, file e27ce42f-8645-2581-e053-d805fe0acbaa 120
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO), file e27ce429-3c23-2581-e053-d805fe0acbaa 119
Management of myeloma: an Italian perspective, file e27ce426-ce62-2581-e053-d805fe0acbaa 112
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, file e27ce42f-8b46-2581-e053-d805fe0acbaa 106
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib., file e27ce427-8454-2581-e053-d805fe0acbaa 99
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, file e27ce427-76e7-2581-e053-d805fe0acbaa 95
Lenalidomide maintenance with or without prednisone in newly diagnosed myeloma patients: A pooled analysis, file e27ce430-5f1c-2581-e053-d805fe0acbaa 95
International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, file e27ce426-d3d6-2581-e053-d805fe0acbaa 94
Autologous Transplantation in Elderly Multiple Myeloma Patients: Is the Procedure Cost Effective?, file e27ce427-822a-2581-e053-d805fe0acbaa 91
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis, file e27ce42f-6e99-2581-e053-d805fe0acbaa 81
Safety of thalidomide in newly diagnosed elderly myeloma patients: an individual patient data meta-analysis of six randomized trials., file e27ce426-ebf4-2581-e053-d805fe0acbaa 80
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report, file e27ce427-b676-2581-e053-d805fe0acbaa 75
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma, file e27ce427-0a2c-2581-e053-d805fe0acbaa 71
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma, file e27ce430-925f-2581-e053-d805fe0acbaa 69
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies, file e27ce42f-9bd7-2581-e053-d805fe0acbaa 64
The European Hematology Association roadmap for European Hematology Research: A consensus document, file e27ce42b-0949-2581-e053-d805fe0acbaa 54
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study., file e27ce427-e241-2581-e053-d805fe0acbaa 52
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study, file e27ce435-83b6-2581-e053-d805fe0acbaa 51
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients., file e27ce426-f87f-2581-e053-d805fe0acbaa 50
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies., file e27ce426-f477-2581-e053-d805fe0acbaa 46
Stem Cell Transplantation in Multiple Myeloma, file e27ce42f-5d6d-2581-e053-d805fe0acbaa 46
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life, file e27ce432-1108-2581-e053-d805fe0acbaa 46
Elotuzumab therapy for relapsed or refractory multiple myeloma, file e27ce432-4439-2581-e053-d805fe0acbaa 29
Novel treatment paradigm for elderly patients with multiple myeloma., file e27ce426-ea1f-2581-e053-d805fe0acbaa 23
Hematopoietic stem and progenitor cell composition in peripheral blood and in mobilized CD34+ cells harvests., file e27ce427-5214-2581-e053-d805fe0acbaa 23
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis, file e27ce435-863a-2581-e053-d805fe0acbaa 22
Totale 29235
Categoria #
all - tutte 30982
article - articoli 0
book - libri 0
conference - conferenze 709
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31691


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20181523 0000 0157 180222 248300214202
2018/20194701 231268250272 294220 299480 460517826584
2019/20206512 516440429702 499461 488432 1294430404417
2020/20215657 353462404357 490539 498480 398574546556
2021/20226983 616434458917 768396 729440 450311865599
2022/20231557 213405781158 00 00 0000
Totale 29492